The first row is for desktop, and second row is for Tab and Mobile.
You can right click on this text and use Navigator for easy editing. This text message is hidden on all screens using Advanced/responsive tab on left.

Topic: Medical Equipment


September 21, 2020

Status: Active

Share on facebook
Share on twitter
Share on linkedin

QUIT-Mobile is a screening and brief intervention (SBI) aimed at providing a feasible and sustainable tool for primary care clinics for addressing primary care patients’ risky drug use (moderate use) to prevent progression to serious substance use disorders requiring referral to substance use specialty care services. It adds on mobile phone self-monitoring and feedback to support long-term (12 months or more) the efficacious QUIT study which reduced drug use by 33-41% in patients at 3-month follow-up.

QUIT-Mobile is an Effectiveness-Implementation Hybrid Type 1 design consisting of a single-blind, 3-arm, RCT with diverse adult FQHC primary care patients with risky drug use (ASSIST score 4-26), randomized to 3 conditions (n=320/arm, n=960 total): 1) QUIT-Mobile; 2) standard QUIT; 3) Usual Care. Qualitative data on implementation facilitators and barriers will inform future scale-up and sustainability, in addition to cost data and cost-effectiveness analysis The study is led by Principal Investigators, Drs. Lillian Gelberg and Dallas Swendeman, and directed by Stephanie Sumstine (Intervention and Mobile Technology Director), Efren Aguilar (Fieldwork Director) and Whitney Akabike (Project Manager).